There are inconsistent findings regarding the effect of lipid-lowering agents on non-alcoholic fatty liver disease (NAFLD). Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is an important player in cholesterol homeostasis and intracellular lipogenesis, and PCSK9 inhibitors (PCSK9-i) have been found to be efficient for pharmacological management of hyperlipidemia.

The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition / A.A. Momtazi-Borojeni, M. Banach, M. Ruscica, A. Sahebkar. - In: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. - ISSN 1751-2433. - (2022 Oct 05), pp. 1-10. [Epub ahead of print] [10.1080/17512433.2022.2132229]

The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition

M. Ruscica
Writing – Review & Editing
;
2022

Abstract

There are inconsistent findings regarding the effect of lipid-lowering agents on non-alcoholic fatty liver disease (NAFLD). Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is an important player in cholesterol homeostasis and intracellular lipogenesis, and PCSK9 inhibitors (PCSK9-i) have been found to be efficient for pharmacological management of hyperlipidemia.
Non-alcoholic fatty liver; Nonalcoholic steatohepatitis; PCSK9
Settore MED/04 - Patologia Generale
Article (author)
File in questo prodotto:
File Dimensione Formato  
Amir Abbas Momtazi-Borojeni.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.53 MB
Formato Adobe PDF
1.53 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/939746
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact